IP Library › Patent Application 13577295
Patent Application
App. No. 13/577,295

METHODS AND COMPOSITIONS FOR CANCER IMMUNOTHERAPY USING FLAGELLIN-TUMOR ASSOCIATED ANTIGEN FUSION PROTEIN EXPRESSING TUMOR CELLS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/577,295
Abstract

Provided are methods for inducing an anti-tumor immune response by immunizing a mammal with a composition comprising a tumor cell which expresses a NLR ligand and/or TLR ligand-TAA fusion protein or with an activated DC which has internalized a tumor cell which expresses an NLR- and/or TLR ligand-TAA fusion protein.

Claims (48)

1 . A composition comprising a dendritic cell (DC), wherein said DC has internalized a tumor cell expressing a fusion protein, said fusion protein comprising:

(a) a Toll-like receptor (TLR) ligand and a tumor-associated antigen (TAA), or

(b) a Nod-like receptor (NLR) ligand and a tumor-associated antigen (TAA), or

(c) a Toll-like receptor (TLR) ligand, a Nod-like receptor (NLR) ligand, and a tumor-associated antigen (TAA).

2 - 3 . (canceled)

4 . A method for inducing an anti-tumor immune response in a mammal in need thereof comprising administering to said mammal an immunogenically effective amount of the composition of claim 1 .

5 . A method for treating a cancer in a patient in need of such treatment comprising administering to said patient the composition of claim 1 in an effective amount for eliciting an anti-tumor immune response.

6 . A method for inducing an anti-tumor immune response in a mammal in need thereof comprising administering to said mammal an immunogenically effective amount of a composition comprising a tumor cell expressing a fusion protein, wherein said fusion protein comprises:

(a) a TLR ligand and a tumor-associated antigen (TAA), or

(b) a Nod-like receptor (NLR) ligand and a tumor-associated antigen (TAA), or

(c) a Toll-like receptor (TLR) ligand, a Nod-like receptor (NLR) ligand, and a tumor-associated antigen (TAA).

7 . A method for treating a cancer in a patient in need of such treatment comprising administering to said patient a composition comprising a tumor cell expressing a fusion protein, wherein said fusion protein comprises:

(a) a Toll-like receptor (TLR) ligand and a tumor associated antigen (TAA), in an effective amount for eliciting an anti-tumor immune response, or

(b) a Nod-like receptor (NLR) ligand and a tumor-associated antigen (TAA), or

(c) a Toll-like receptor (TLR) ligand, a Nod-like receptor (NLR) ligand, and a tumor-associated antigen (TAA).

8 - 11 . (canceled)

12 . The composition of claim 1 , wherein said TLR ligand is a polypeptide.

13 . The composition of claim 12 , wherein said TLR ligand is a flagellin or profilin-like protein (PLP), or a fragment thereof.

14 . The composition of claim 1 , wherein said tumor cell has been transfected with a vector expressing said fusion protein.

15 . The composition of claim 1 , wherein said DC is an autologous cell.

16 . The composition of claim 1 , or wherein said tumor cell is lethally irradiated prior to internalization by said DC.

17 . The composition of claim 1 , or wherein said DC has phagocytosed said tumor cell.

18 . The method of claim 4 , wherein said DC has phagocytosed said tumor cell.

19 . The method of claim 5 , wherein said DC has phagocytosed said tumor cell.

20 . The method of claim 4 , wherein said anti-tumor immune response comprises a CD4 or CD8 T cell-mediated immune response.

21 . The method of claim 6 , wherein said anti-tumor immune response comprises a CD4 or CD8 T cell-mediated immune response.

22 . The method of claim 6 , wherein said mammal is a human.

23 . The method of claim 7 , wherein said patient is a human.

24 . The composition of claim 1 , wherein said NLR ligand is selected from the group consisting of a flagellin, an anthrax toxin, and a Staphylococcus aureus toxin, or a fragment thereof.

25 . The composition of claim 1 , wherein said tumor cell is an autologous cell.

26 . The method of claim 4 , wherein said tumor cell is an autologous cell.

27 . The method of claim 5 , wherein said tumor cell is an autologous cell.

28 . The method of claim 6 , wherein said tumor cell is an autologous cell.

29 . The method of claim 4 , wherein said mammal is a human.

30 . The method of claim 4 , wherein said DC is an autologous cell.

31 . The method of claim 5 , wherein said DC is an autologous cell.

32 . The composition of claim 1 (a), wherein said TLR ligand is also an NLR ligand.

33 . The composition of claim 1 (b), wherein said NLR ligand is also a TLR ligand.

34 . The composition of claim 1 (a), wherein said fusion protein further comprises a distinct NLR ligand.

35 . The composition of claim 1 (b), wherein said fusion protein further comprises a distinct TLR ligand.

36 . The composition of claim 32 , wherein said TLR ligand is profilin-like protein (PLP) and said NLR ligand is anthrax toxin, or a fragment thereof.

37 . The method of claim 4 , wherein said tumor cell is lethally irradiated.

38 . The method of claim 5 , wherein said tumor cell is lethally irradiated.

39 . The method of claim 6 , wherein said tumor cell is lethally irradiated.

40 . The method of claim 5 , wherein said patient is a human.

41 . The method of claim 7 , wherein said tumor cell is an autologous cell.

42 . The composition of claim 34 , wherein said TLR ligand is profilin-like protein (PLP) and said NLR ligand is anthrax toxin, or a fragment thereof.

43 . The method of claim 7 , wherein said tumor cell is lethally irradiated.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2012
From: BLANDER, JULIE MAGARIAN; GARAUDE, JOHAN
To: MOUNT SINAI SCHOOL OF MEDICINE
Reel/Frame 028979/0605 →